Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon alfa-2b in Essential Thrombocythaemia (ROP-ET)
NCT06514807Phase 3Active, not recruiting
- Sponsor
- AOP Health
- Start
- Dec 2023
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of ropeginterferon alfa-2b in essential thrombocythemia (ET), sponsored by AOP Health. Primary endpoints: Durable (for at least 3 months) peripheral blood count remission, Absence of haemorrhagic or thrombotic events and absence of disease progression at Month 12 and 1 more. Started Dec 2023; status: active, not recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT06514807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514807.